The study adopts a multicenter, single-arm, phase 1–2 design (NCT03784599), encompassing patients with EGFRm+ NSCLC displaying HER2 overexpression while experiencing progression on osimertinib. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.